35 results on '"Mehravaran, H."'
Search Results
2. Fixed Point Theorems for F-Contractions in Dislocated Sb-Metric Spaces.
- Author
-
Mehravaran, H., Khanehgir, M., and Allahyari, R.
- Subjects
- *
FIXED point theory , *MATHEMATICS , *METRIC geometry , *ABBREVIATIONS , *MONOIDS - Abstract
In this paper, we introduce the notion of dislocated Sb-metric space and describe some fixed point theorems concerning F-contraction in the setup of such spaces. We provide some examples to verify the effectiveness and applicability of our main results. [ABSTRACT FROM AUTHOR]
- Published
- 2019
3. A Family of Measures of Noncompactness in the Locally Sobolev Spaces and Its Applications to Some Nonlinear Volterra Integrodifferential Equations
- Author
-
Mehravaran, H., primary, Khanehgir, M., additional, and Allahyari, R., additional
- Published
- 2018
- Full Text
- View/download PDF
4. Uptake and partitioning of32P and65Zn by white clover as affected by eleven isolates of mycorrhizal fungi
- Author
-
Mehravaran, H., primary, Mozafar, A., additional, and Frossard, E., additional
- Published
- 2000
- Full Text
- View/download PDF
5. Noise Pollution Evaluation Method for Identification of the Critical Zones in Tehran.
- Author
-
Mehravaran, H., Zabani, S., Nabi Bidhendi, Gh. R., Ghousi, R., and Keshavarzi Shirazi, H.
- Abstract
The equivalent noise level in large cities has been growing due to the population growth, uncontrolled production of cars, and the existence of worn out cars. On the other hand, heavy traffic has increased the amount of noise problems for residents of medical and educational centers, research institutes and residential area (or sensitive centers to noise) built in highway bounds and it has also caused and added to their stress and discomfort. This paper presents the results of measurement of equivalent noise level (L
cq ) on various roads in Tehran. The noise maps and color contours resulted from modeling of the noise emission sources, and the critical zones in these area have been identified through the noise pollution aspect arid have been studied and the appropriate solutions have been suggested. ft is possible to decrease the level of noise pollution in those zones effectively, through modeling and identifying the critical zones and also by presenting noise control solution. [ABSTRACT FROM AUTHOR]- Published
- 2011
6. Uptake and partitioning of P and Zn by white clover as affected by eleven isolates of mycorrhizal fungi.
- Author
-
Mehravaran, H., Mozafar, A., and Frossard, E.
- Published
- 2000
- Full Text
- View/download PDF
7. Uptake and partitioning of 32P and 65Zn by white clover as affected by eleven isolates of mycorrhizal fungi
- Author
-
Mehravaran, H., Mozafar, A., and Frossard, E.
- Abstract
We compared the effect of eleven mycorrhizal fungi populations (Glomus spp.) from two different climatic regions (Iran vs. Switzerland) on the uptake and partitioning of 32P and 65Zn by white clover (Trifolium repens L. var. Milkanova). Fungi significantly differed in the colonization of roots with hyphae, vesicles or arbuscules and in their effect on the uptake of 32P or 65Zn by white clover. Fungi also differed in their effects on the percentages of 32P or 65Zn transported to the plant tops. There was no relationship between the uptake of 32P and that of 65Zn in plants colonized by different fungi. Isolates Z7 and Q12 (from Iran) were superior to Swiss isolates for their effect on the uptake of zinc (Zn) by white clover. Among the Swiss isolates, that from Langwiese and Hausweid resulted in the highest and lowest partitioning of both 32P and 65Zn to the plant tops, respectively. We conclude that the effectiveness of vesicular arbuscular mycorrhizae in uptake of phosphorus (P) and Zn may be nutrient specific and that some fungal isolates may also affect the relative partitioning of P and Zn between plant roots and tops.
- Published
- 2000
- Full Text
- View/download PDF
8. Prevalence of hepatitis c virus genotype 3a in patients with hodgkin and non-hodgkin lymphoma
- Author
-
Radmehr, H., Makvandi, M., Samarbafzadeh, A., Teimoori, A., Neisi, N., Mojtaba Rasti, Abasifar, S., Soltani, H., Abbasi, S., Kiani, H., Mehravaran, H., Azaran, A., and Shahani, T.
9. Association of HHV-6 with Hodgkin and non Hodgkin lymphoma
- Author
-
Kiani, H., manoochehr makvandi, Samarbafzadeh, A., Teimoori, A., Nisi, N., Mehravaran, H., Radmehr, H., Hosseini, Z., Haghi, A., Shahani, T., Varnaseri, M., and Ranjbari, N.
- Subjects
Non-hodgkin lymphoma ,immune system diseases ,viruses ,hemic and lymphatic diseases ,lcsh:QR1-502 ,Human herpes virus 6 ,virus diseases ,Original Article ,biochemical phenomena, metabolism, and nutrition ,lcsh:Microbiology ,Hodgkin lymphoma ,Nested PCR - Abstract
Background and Objectives: Human Herpes 6 virus (HHV-6) could remain latent and chronic in the host cells after primary infection. HHV-6 genome encodes certain trans activation proteins which may results in development of malignantlymphoma. The association of human herpes six virus (HHV-6) infection and Hodgkin and Non-Hodgkin lymphomas is strongly supported by epidemiological studies. The aim of this study was to determine the prevalence of HHV-6 among the patients with Hodgkin, Non- Hodgkin`s lymphoma. Materials and Methods: Overall 44 blocks of formalin-fixed, paraffin-embedded of the patients including 22(50%) Hodgkin and 22(50%) Non-Hodgkin Lymphoma were collected. Initially the section of 5μm-thickness were prepared from the formalin-fixed, paraffin-embedded tissue blocks. Then the deparaphinazation was carried out for each sample. The DNA was extracted, followed by nested PCR for detection of HHV-6. Based on PCR product size and sequencing, the HHV-6 A or B subtypes were characterized. Results: 12/22(54.54%) cases of Hodgkin and 8/22 (36.36%) Non-Hodgkin’s lymphoma were shown as positive for HHV-6. Out of 12 positive HHV-6 in Hodgkin lymphoma, 10 patients (45.45%) belonged to variant A while 2 cases (9.09%) were found positive for both HHV-6A and HHV-6B. All the Non Hodgkin samples (n=8, 36.36%) showed positive for HHV-6 variant A. Conclusion: High prevalence of HHV-6 was found among the patients with Hodgkin and Non-Hodgkin’s lymphoma. Two patients with Hodgkin lymphoma had mixed HHV-6A and HHV-6B infections. It is recommended patients with Hodgkin and Non-Hodgkin should be screened for HHV-6 detection before chemotherapy.
10. Vesicular–arbuscular mycorrhizae in the Chenopodiaceae and Cruciferae: do they occur?
- Author
-
Hirrel, Marc C., primary, Mehravaran, H., additional, and Gerdemann, J. W., additional
- Published
- 1978
- Full Text
- View/download PDF
11. Vesicular-arbuscular mycorrhizae in the Chenopodiaceae and Cruciferae: do they occur?
- Author
-
Gerdemann, J. W., Hirrel, Marc C., and Mehravaran, H.
- Published
- 1978
12. Imaging patterns of Lophomonas blattarum infection in the respiratory tract: a registry-based analysis.
- Author
-
Taheri A, Fakhar M, Sharifpour A, Banimostafavi E, SafaNavaei S, Abedi S, Mehravaran H, Aliyali M, Shafahi A, and Delpzir A
- Subjects
- Humans, Adult, Middle Aged, Aged, Cross-Sectional Studies, Lung diagnostic imaging, Registries, Lung Diseases, Bronchiectasis
- Abstract
Background: Lophomonas blattarum is an emerging protozoan that mostly infects the lower respiratory tract and causes pulmonary lophomoniasis. Radiologic findings in patients with pulmonary lophomoniasis have yet to be studied. Thus, we conducted a registry-based clinical investigation to evaluate the radiologic findings of lophomoniasis., Methods: In this cross-sectional study, 34 Lophomonas positive patients were enrolled. Demographic data, relevant characteristics, and radiologic findings of the patients were recorded and analyzed., Results: Thirty-four (male = 18, female = 16) patients with an average age of 52.21 ± 20.48 years old were examined. Radiological findings such as Alveolar consolidation (26.5%), Ground glass opacity (5.9%), Centrilobular nodules (23.5%), Tree -in- bud (38.2%), Cavitation (23.5%), Pleural effusion (23.5%), Interstitial opacity (8.8%), Lymphadenopathy (23.5%), Bronchocele (5.9%), Bronchiectasis (29.4%), Nodules (8.8%) and Mass (11.8%) were obtained, that the frequency of all radiological findings was less than 50%., Conclusion: In this study, the most common radiological findings in patients with lophomoniasis were tree-in-bud nodules, alveolar consolidation, bronchiectasis, and centrilobular nodules which were mostly seen in the right lung and its middle and lower lobes. Given that the radiologic findings of this disease are unknown, it can be considered in differential diagnosis., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
13. Global mortality and readmission rates following COPD exacerbation-related hospitalisation: a meta-analysis of 65 945 individual patients.
- Author
-
Waeijen-Smit K, Crutsen M, Keene S, Miravitlles M, Crisafulli E, Torres A, Mueller C, Schuetz P, Ringbæk TJ, Fabbian F, Mekov E, Harries TH, Lun CT, Ergan B, Esteban C, Quintana Lopez JM, López-Campos JL, Chang CL, Hancox RJ, Shafuddin E, Ellis H, Janson C, Suppli Ulrik C, Gudmundsson G, Epstein D, Dominguez J, Lacoma A, Osadnik C, Alia I, Spannella F, Karakurt Z, Mehravaran H, Utens C, de Kruif MD, Ko FWS, Trethewey SP, Turner AM, Bumbacea D, Murphy PB, Vermeersch K, Zilberman-Itskovich S, Steer J, Echevarria C, Bourke SC, Lane N, de Batlle J, Sprooten RTM, Russell R, Faverio P, Cross JL, Prins HJ, Spruit MA, Simons SO, Houben-Wilke S, and Franssen FME
- Abstract
Background: Exacerbations of COPD (ECOPD) have a major impact on patients and healthcare systems across the world. Precise estimates of the global burden of ECOPD on mortality and hospital readmission are needed to inform policy makers and aid preventive strategies to mitigate this burden. The aims of the present study were to explore global in-hospital mortality, post-discharge mortality and hospital readmission rates after ECOPD-related hospitalisation using an individual patient data meta-analysis (IPDMA) design., Methods: A systematic review was performed identifying studies that reported in-hospital mortality, post-discharge mortality and hospital readmission rates following ECOPD-related hospitalisation. Data analyses were conducted using a one-stage random-effects meta-analysis model. This study was conducted and reported in accordance with the PRISMA-IPD statement., Results: Data of 65 945 individual patients with COPD were analysed. The pooled in-hospital mortality rate was 6.2%, pooled 30-, 90- and 365-day post-discharge mortality rates were 1.8%, 5.5% and 10.9%, respectively, and pooled 30-, 90- and 365-day hospital readmission rates were 7.1%, 12.6% and 32.1%, respectively, with noticeable variability between studies and countries. Strongest predictors of mortality and hospital readmission included noninvasive mechanical ventilation and a history of two or more ECOPD-related hospitalisations <12 months prior to the index event., Conclusions: This IPDMA stresses the poor outcomes and high heterogeneity of ECOPD-related hospitalisation across the world. Whilst global standardisation of the management and follow-up of ECOPD-related hospitalisation should be at the heart of future implementation research, policy makers should focus on reimbursing evidence-based therapies that decrease (recurrent) ECOPD., Competing Interests: Conflict of interest: K. Waeijen-Smit, M. Crutsen, S. Keene, T.J. Ringbæk, F. Fabbian, C-t. Lun, B. Ergan, C. Estebam, J.M. Quintana Lopez, C.L. Chang, R.J. Hancox, E. Shafuddin, H. Ellis, C. Janson, G. Gudmundsson, D. Epstein, A. Lacoma, C. Osadnik, I. Alia, F. Spannella, Z. Karakurt, H. Mehravaran, C. Utens, M.D. de Kruif, F.W.S. Ko, S.P. Trethewey, K. Vermeersch, S. Zilberman-Itskovich, C. Echevarria, R.T.M. Sprooten, P. Faverio, H.J. Prins and S. Houben-Wilke have no grants or personal fees to report. Conflict of interest: M. Miravitlles has received speaker fees from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, Menarini, Kamada, Takeda, Zambon, CSL Behring, Specialty Therapeutics, Janssen, Grifols and Novartis, consulting fees from AstraZeneca, Atriva Therapeutics, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, CSL Behring, Inhibrx, Ferrer, Menarini, Mereo Biopharma, Spin Therapeutics, ONO Pharma, Palobiofarma SL, Takeda, Novartis, Novo Nordisk, Sanofi and Grifols and research grants from Grifols. Conflict of interest: E. Crisafulli has received honoraria for lecturing, scientific advisory boards and participation in clinical studies for AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Menarini, Novartis, Qbgroup and Sanofi. Conflict of interest: A. Torres reports speaker/consulting honoraria from Pfizer, MSD, Janssen and Biomerieux. Conflict of interest: C. Mueller has received research support from the Swiss National Science Foundation, the Swiss Heart Foundation, the University of Basel, the University Hospital Basel, the KTI, Abbott, Beckman Coulter, BRAHMS, Idorsia, LSI-Medience, Ortho Diagnostics, Novartis, Roche, Siemens, SpinChip and Singulex, as well as speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi Sankyo, Idorsia, Novartis, Osler, Roche, SpinChip and Sanofi, all outside the submitted work. Conflict of interest: P. Schuetz has received grants from Nestle, Abbot, bioMerieux and Thermofisher outside the submitted work. Conflict of interest: E. Mekov has received grants and personal fees from Chiesi, and speaker or consulting fees from AstraZeneca and Chiesi. Conflict of interest: T.H. Harries is supported by a National Institute for Health and Care Research Academic Clinical Lectureship. Conflict of interest: J.L. López-Campos has received honoraria during the last 3 years for lecturing, scientific advice, participation in clinical studies or writing for publications for (alphabetical order): AstraZeneca, Bial, Boehringer, Chiesi, CSL Behring, Faes, Ferrer, Gebro, Grifols, GSK, Megalabs, Menarini and Novartis. Conflict of interest: C.S. Ulrik has received personal fees and grants from AstraZeneca, Chiesi, Boehringer Ingelheim, GSK, Novartis, Sanofi, Menarini, TEVA, ALK-Abello, Takeda, Orion Pharma, TFF Pharmaceuticals and Covis Pharma outside the submitted work. Conflict of interest: J. Dominguez has received honoraria for lectures from Oxford Immunotec (UK) and received payments for license transference from GenID (Germany), and grants from La Fundació La Marató TV3, Instituto de Salud Carlos III (CP03/00112), Catalan Pulmonology Society (SOCAP), Catalan Pulmonology Foundation (FUCAP) and Spanish Society of Pulmonology and Thoracic Surgery (SEPAR). Conflict of interest: A.M. Turner reports research grants outside the submitted work from AstraZeneca, Resmed, Phillips, Chiesi, Grifols, CSL Behring and NIHR, and honoraria from GSK and Boehringer Ingelheim. Conflict of interest: D. Bumbacea has received grants and personal fees in the last 3 years from AstraZeneca, Eli Lilly, Novartis, Sanofi and Synairgen outside of the submitted work. Conflict of interest: PBM has received grants and personal fees from Philips, ResMed, Breas, Chiesi, Fischer & Paykel and, Sanofi outside the submitted work. Conflict of interest: J. Steer has received grants and honoraria, outside the submitted work, from Chiesi, Menarini Group, AstraZeneca and Pfizer. Conflict of interest: S.C. Bourke has received research grants from GSK (BEC COPD IRAS 285200), and additional support from Radiometer for an NIHR-funded study (NIVOW IRAS 313485), Philips, ResMed, and Pfizer Open Air, took part in clinical advisory boards with Philips and AstraZeneca, and has received honoraria from Boehringer Ingelheim, Chiesi, GSK, and AstraZeneca. Conflict of interest: N. Lane reports research grants from Bright Northumbria and The ResMed Foundation; and nonfinancial support from Chiesi and BREAS outside the submitted work. Conflict of interest: J. de Batlle acknowledges receiving financial support from Instituto de Salud Carlos III (Miguel Servet 2019: CP19/00108), co-funded by the European Social Fund, “Investing in your future”. Conflict of interest: R. Russell has received personal fees, outside of the submitted work, from AstraZeneca, Chiesi, Covis, GlaxoSmithKline and Boehringer Ingelheim. Conflict of interest: J.L. Cross has received grants from National Institute of Health Research. Conflict of interest: M.A. Spruit has received grants from the Netherlands Lung Foundation, Stichting Asthma Bestrijding, AstraZeneca, Boehringer Ingeheim, TEVA and CHIESI outside the submitted work. Conflict of interest: S.O. Simons has received grants and personal fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Chiesi outside the submitted work. Conflict of interest: F.M.E. Franssen has received grants and personal fees from AstraZeneca, Chiesi, Boehringer Ingelheim, Glaxosmithkline, Novartis and MSD outside the submitted work. Conflict of interest: All authors declare no conflicts of interest in relation to the present study., (Copyright ©The authors 2024.)
- Published
- 2024
- Full Text
- View/download PDF
14. Geospatial Analysis and Molecular Epidemiologic Study of Emerging Pulmonary Lophomoniasis in Iran: A National Registry-Based Study.
- Author
-
Ghatee MA, Nakhaei M, Sharifpour A, Fakhar M, Mohamadi N, Soleymani M, Abedi S, Aliyali M, and Mehravaran H
- Abstract
Introduction: Bronchopulmonary lophomoniasis (BPL) is a protozoan pulmonary disease that has been reported sporadically, but its incidence has been increasing. However, the epidemiology and risk factors of the disease have not been clearly identified. The current study aims to identify BPL cases molecularly and assess the demographic and some environmental factors for the first time on the prevalence of BPL as a national registry-based study in Iran. Methodology . The study tested 960 patients with lower respiratory tract symptoms whose bronchoalveolar lavage samples were submitted from seven provinces of Iran to the Iranian National Registry Center for Lophomoniasis. They were tested for BPL by a newly developed polymerase chain reaction test. The study assessed the association of Normalized difference vegetation index (NDVI), digital elevation model (DEM), and geographic latitude as environmental factors and sex and age as demographic factors on the prevalence of BPL. Geospatial information systems methods and chi-squared and Pearson's correlation tests were used for the assessment of geographical and environmental factor effects and statistical analysis, respectively., Results: Of the 960 patients, 218 (22.7%) tested positive for BPL; the highest and lowest prevalence rates were reported from the south and northeast of Iran, respectively. The study found a correlation between geographic latitude and age with BPL prevalence, but no association was found for gender, NDVI, or DEM. Most patients were over 40 years old, and the rate of disease was higher in southern latitudes., Conclusion: Age and geographical latitude were found to be risk factors for BPL. More exposure to dust and/or chronic pulmonary problems may explain the higher prevalence of the disease in older adults. Higher rates of BPL in lower latitudes may be due to warmer weather and longer days, which can confine individual activities indoors and result in more contact with domestic insects and infected dust., Competing Interests: The author(s) declare(s) that they have no conflicts of interest., (Copyright © 2023 Mohammad Amin Ghatee et al.)
- Published
- 2023
- Full Text
- View/download PDF
15. Efficacy and safety of adding fluoxetine to the treatment regimen of hospitalized patients with non-critical COVID-19 pneumonia: A double-blind randomized, placebo-controlled clinical trial.
- Author
-
Sedighi F, Zarghami M, Alizadeh Arimi F, Moosazadeh M, Ala S, Ghasemian R, Mehravaran H, and Elyasi F
- Subjects
- Female, Humans, Male, Middle Aged, Antidepressive Agents, Second-Generation administration & dosage, Antidepressive Agents, Second-Generation adverse effects, Antidepressive Agents, Second-Generation therapeutic use, Anxiety complications, C-Reactive Protein analysis, Depression complications, Double-Blind Method, Intensive Care Units, Patient Discharge, Placebos, Respiration, Artificial, SARS-CoV-2, Selective Serotonin Reuptake Inhibitors administration & dosage, Selective Serotonin Reuptake Inhibitors adverse effects, Selective Serotonin Reuptake Inhibitors therapeutic use, Treatment Outcome, Inflammation complications, Inflammation drug therapy, COVID-19 complications, COVID-19 mortality, COVID-19 therapy, Fluoxetine administration & dosage, Fluoxetine adverse effects, Fluoxetine therapeutic use, Hospitalization, Pneumonia, Viral complications, Pneumonia, Viral mortality, Pneumonia, Viral therapy
- Abstract
Introduction: Selective serotonin reuptake inhibitors are considered the drugs, whose effectiveness in viral pandemics has been studied. The aim of this study was to evaluate of adding fluoxetine to the treatment regimen of patients with COVID-19 pneumonia., Methods: This study was a double-blind randomized placebo controlled clinical trial .36 patients in the fluoxetine and 36 patients in the placebo group were enrolled. Patients in the intervention group were first treated with fluoxetine 10 mg for 4 days and then the dose of 20 mg was continued for 4 weeks. Data analysis was conducted using SPSS V. 22.0., Results: There was no statistically significant difference between the two groups in terms of clinical symptoms at the beginning of the study and also the score of anxiety and depression, oxygen saturation at the time of hospitalization, mid-hospitalization and discharge periods. The need for mechanical ventilator support (p = 1.00), the need for admission in the intensive care unit (ICU) (p = 1.00), rate for mortality (p = 1.00), and discharge with relative recovery (p = 1.00) were not significantly different between the two groups. The distribution of CRP within the study groups showed a significant decrease during different time periods (p = 0.001), and although there was no statistically significant difference between the two groups on the first day (p = 1.00) and at discharge (p = 0.585), mid-hospital CRP showed a significant decrease in the fluoxetine group (p = 0.032)., Conclusion: Fluoxetine resulted in a faster reduction of patients' inflammation without association with depression and anxiety., (© 2023 The Authors. Neuropsychopharmacology Reports published by John Wiley & Sons Australia, Ltd on behalf of The Japanese Society of Neuropsychopharmacology.)
- Published
- 2023
- Full Text
- View/download PDF
16. Frequency of delirium and its associated factors among COVID-19 inpatients in Iran.
- Author
-
Alizadeh Arimi F, Zarghami M, Moosazadeh M, Mehravaran H, Sedighi F, Ghasemian R, and Elyasi F
- Subjects
- Humans, Inpatients, Iran epidemiology, Cross-Sectional Studies, Intensive Care Units, Delirium diagnosis, Delirium epidemiology, Delirium etiology, COVID-19 complications, COVID-19 epidemiology
- Abstract
Background and Aim: Delirium has been presented as the leading cause of sudden change in the mental state of patients with coronavirus disease 2019 (COVID-19). Given that the delayed diagnosis of such a dysfunction is often associated with excess mortality, it seems essential to devote vastly more attention to this significant clinical characteristic., Materials and Methods: This cross-sectional study was performed on 309 patients [viz. 259 cases hospitalized in general wards and 50 individuals admitted to the intensive care unit (ICU)]. For this purpose, a Demographic-Clinical Information Questionnaire, the Confusion Assessment Method (CAM), the Confusion Assessment Method for the ICU (CAM-ICU), the Richmond Agitation-Sedation Scale (RASS) and face-to-face interviews were completed by a trained senior psychiatry resident. The data analysis was further done with the SPSS Statistics V22.0 software package., Results: Out of 259 patients admitted to the general wards and 50 cases in the ICU due to COVID-19, 41 (15.8%) and 11 (22%) individuals were diagnosed with delirium, respectively. As well, a significant relationship was observed between the incidence rate of delirium and age (p < 0.001), level of education (p < 0.001), hypertension (HTN) (p = 0.029), a history of stroke (p = 0.025), a history of ischemic heart disease (IHD) (p = 0.007), a history of psychiatric disorders, a history of cognitive impairment (p < 0.001), use of hypnotic and antipsychotic medications (p < 0.001) and a history of substance abuse (p = 0.023). Among 52 patients with delirium, only 20 cases had received psychiatric consultation by consultation-liaison psychiatry service for the possibility of delirium., Conclusion: In view of the high frequency of delirium among COVID-19 inpatients, their screening for this important mental state should be a priority in clinical settings., (© 2023 The Authors. The Clinical Respiratory Journal published by John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
17. Fiberoptic Bronchoscopic Findings in Patients Suffering from Emerging Pulmonary Lophomoniasis: A First Registry-Based Clinical Study.
- Author
-
Aliyali M, Taheri A, Fakhar M, Sharifpour A, Nakhaei M, Abedi S, Mehravaran H, and Safanavaei S
- Abstract
Background: Lophomonas blattarum is an emerging protozoan agent that mainly infects the lower respiratory system, causing pulmonary lophomoniasis. The bronchoscopic findings in patients with pulmonary lophomoniasis have not been investigated yet. Accordingly, we assess the bronchoscopic findings of lophomoniasis in patients suffering from pulmonary lophomoniasis through a registry-based clinical study., Methods: In this retrospective study, of 480 patient candidates for bronchoscopy, 50 Lophomonas -positive patients were enrolled. Demographic data, relevant characteristics, and bronchoscopy findings of the patients were recorded and analyzed., Results: Overall, 50 (male = 32, female = 18) patients with an average age of 61.8 ± 13.3 years were examined. Nineteen patients (38%) had normal bronchoscopic findings, and 31 patients (62%) had abnormal bronchoscopic findings. According to the severity index, most (52%) of patients had mild severity, followed by moderate (30%) and severe (18%) cases. The highest involvement was in the right lung bronchus (46%), and the lowest was in the carina (8%). Furthermore, purulent and mucosal secretions in the right and left lung bronchus were the most abnormalities found in different anatomical locations., Conclusion: For the first time, the current study demonstrated that pulmonary lophomoniasis does not have pathognomonic bronchoscopic findings. However, each suspected patient must be checked for lophomoniasis, even with normal bronchoscopic findings, particularly in endemic areas., Competing Interests: The authors declare that they have no conflicts of interest., (Copyright © 2022 Masoud Aliyali et al.)
- Published
- 2022
- Full Text
- View/download PDF
18. Non-effectiveness of Ivermectin on Inpatients and Outpatients With COVID-19; Results of Two Randomized, Double-Blinded, Placebo-Controlled Clinical Trials.
- Author
-
Rezai MS, Ahangarkani F, Hill A, Ellis L, Mirchandani M, Davoudi A, Eslami G, Roozbeh F, Babamahmoodi F, Rouhani N, Alikhani A, Najafi N, Ghasemian R, Mehravaran H, Hajialibeig A, Navaeifar MR, Shahbaznejad L, Rahimzadeh G, Saeedi M, Alizadeh-Navai R, Moosazadeh M, Saeedi S, Razavi-Amoli SK, Rezai S, Rostami-Maskopaee F, Hosseinzadeh F, Movahedi FS, Markowitz JS, and Valadan R
- Abstract
Background: Ivermectin which was widely considered as a potential treatment for COVID-19, showed uncertain clinical benefit in many clinical trials. Performing large-scale clinical trials to evaluate the effectiveness of this drug in the midst of the pandemic, while difficult, has been urgently needed., Methods: We performed two large multicenter randomized, double-blind, placebo-controlled clinical trials evaluating the effectiveness of ivermectin in treating inpatients and outpatients with COVID-19 infection. The intervention group received ivermectin, 0.4mg/kg of body weight per day for 3 days. In the control group, placebo tablets were used for 3 days., Results: Data for 609 inpatients and 549 outpatients were analyzed. In hospitalized patients, complete recovery was significantly higher in the ivermectin group (37%) compared to placebo group (28%; RR, 1.32 [95% CI, 1.04-1.66]; p -value = 0.02). On the other hand, the length of hospital stay was significantly longer in the ivermectin group with a mean of 7.98 ± 4.4 days compared to the placebo receiving group with a mean of 7.16 ± 3.2 days (RR, 0.80 [95% CI, 0.15-1.45]; p -value = 0.02). In outpatients, the mean duration of fever was significantly shorter (2.02 ± 0.11 days) in the ivermectin group versus (2.41 ± 0.13 days) placebo group with p value = 0.020. On the day seventh of treatment, fever ( p -value = 0.040), cough ( p -value = 0.019), and weakness ( p -value = 0.002) were significantly higher in the placebo group compared to the ivermectin group. Among all outpatients, 7% in ivermectin group and 5% in placebo group needed to be hospitalized (RR, 1.36 [95% CI, 0.65-2.84]; p -value = 0.41). Also, the result of RT-PCR on day five after treatment was negative for 26% of patients in the ivermectin group versus 32% in the placebo group (RR, 0.81 [95% CI, 0.60-1.09]; p -value = 0.16)., Conclusion: Our data showed, ivermectin, compared with placebo, did not have a significant potential effect on clinical improvement, reduced admission in ICU, need for invasive ventilation, and death in hospitalized patients; likewise, no evidence was found to support the prescription of ivermectin on recovery, reduced hospitalization and increased negative RT-PCR assay for SARS-CoV-2 5 days after treatment in outpatients. Our findings do not support the use of ivermectin to treat mild to severe forms of COVID-19., Clinical Trial Registration: www.irct.ir IRCT20111224008507N5 and IRCT20111224008507N4., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Rezai, Ahangarkani, Hill, Ellis, Mirchandani, Davoudi, Eslami, Roozbeh, Babamahmoodi, Rouhani, Alikhani, Najafi, Ghasemian, Mehravaran, Hajialibeig, Navaeifar, Shahbaznejad, Rahimzadeh, Saeedi, Alizadeh-Navai, Moosazadeh, Saeedi, Razavi-Amoli, Rezai, Rostami-Maskopaee, Hosseinzadeh, Movahedi, Markowitz and Valadan.)
- Published
- 2022
- Full Text
- View/download PDF
19. Occupational burnout in Iranian health care workers during the COVID-19 pandemic.
- Author
-
Kamali M, Azizi M, Moosazadeh M, Mehravaran H, Ghasemian R, Reskati MH, and Elyasi F
- Subjects
- Cross-Sectional Studies, Female, Health Personnel psychology, Humans, Iran epidemiology, Male, Pandemics, Burnout, Professional epidemiology, Burnout, Professional psychology, COVID-19 epidemiology
- Abstract
Background and Aim: Health care workers (HCWs), mostly frontliners, are encountering numerous physical and psychosocial stressors, and even managing some conflicts over the course of the novel coronavirus disease 2019 (COVID-19). In this respect, the present study was to investigate the prevalence rate of occupational burnout (OB) in such workers during this pandemic., Materials and Methods: This cross-sectional study was conducted between April 6 and May 30, 2020, via an online survey in 31 provinces of Iran, on HCWs selected based on convenience sampling method. For data collection, a socio-demographic information form and the Maslach Burnout Inventory (MBI) was utilized. Descriptive statistics, Chi-square test, and multivariate regression analysis were also applied to test the research hypotheses., Results: In total, 7626 HCWs participated in the present study. Accordingly, 73.2 and 26.8% of the workers were female and male, respectively. As well, 57.8% of the respondents were nurses and 14.4% of the cases were clinicians. Moreover, 44.8% of the participants had thus far worked in isolation wards and 40.3% of these individuals reported working for 4-8 hours with COVID-19 patients. The prevalence rate of OB was 18.3%. Besides, 34.2, 48.7, and 56.1% of the respondents had severe levels of emotional exhaustion (EE), higher depersonalization (DP), and decreased sense of personal accomplishment (PA), respectively. Besides, the HCWs at the age range of 20 to 30, having female gender, no children, and a bachelor's degree, and working in isolation wards showed the higher levels of OB with reference to the Chi-square test results (p < 0.001). Accordingly, the statistical test outcomes demonstrated that a history of physical illnesses (p = 0.001) and psychiatric disorders (p = 0.044) could be the best predictor of OB throughout the first peak of the COVID-19 pandemic., Conclusion: Regarding the high prevalence rate of OB among the HCWs and the remaining COVID-19 journey in Iran, health care managers are recommended to orient the required management and coping strategies toward improving mental health in these individuals., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
20. First Co-morbidity of Lophomonas blattarum and COVID-19 Infections: Confirmed Using Molecular Approach.
- Author
-
Nakhaei M, Fakhar M, Sharifpour A, Banimostafavi ES, Zakariaei Z, Mehravaran H, Saberi R, Safanavaei S, Abedi S, Aliyali M, and Soleimani M
- Subjects
- Adult, Female, Humans, Morbidity, Pandemics, COVID-19 epidemiology, Parabasalidea, COVID-19 Drug Treatment
- Abstract
Introduction: Lophomoniasis is caused by Lophomonas spp., a new emerging protozoan, which commonly affects the human lower respiratory tract. The Lophomonas parasite mostly lives commensally in the hindgut of cockroaches., Case Presentation: We present the case of a 33-year-old woman, 30 weeks pregnant, who had severe COVID-19. She was intubated upon admission and began the routine COVID-19 treatment. To rule out possible super infection dual with COVID-19, microscopic examination of the patient's mini-bronchoalveolar lavage (mini-BAL) specimen, revealed L. blattarum, which was identified by the SSU rRNA-PCR and sequencing approaches (accession number: MZ093069). According to that, the patient was treated successfully with metronidazole., Conclusion: To prevent serious complications, lophomoniasis should be listed in co-morbidity cases of COVID-19 infection during the COVID-19 pandemic worldwide. To the best of our knowledge, this is the first co-infection of Lophomonas blattarum and COVID-19 in the world which has been confirmed using a molecular approach., (© 2021. Witold Stefański Institute of Parasitology, Polish Academy of Sciences.)
- Published
- 2022
- Full Text
- View/download PDF
21. Melatonin effects on sleep quality and outcomes of COVID-19 patients: An open-label, randomized, controlled trial.
- Author
-
Mousavi SA, Heydari K, Mehravaran H, Saeedi M, Alizadeh-Navaei R, Hedayatizadeh-Omran A, and Shamshirian A
- Subjects
- Female, Hospitalization, Humans, Intensive Care Units, Male, Middle Aged, Oxygen blood, COVID-19 physiopathology, Melatonin therapeutic use, Sleep drug effects, COVID-19 Drug Treatment
- Abstract
This trial aims to evaluate the effectiveness of adding melatonin to the treatment protocol of hospitalized coronavirus disease 2019 (COVID-19) patients. This was an open-label, randomized controlled clinical trial in hospitalized COVID-19 patients. Patients were randomized into a treatment arm receiving melatonin plus standard care or a control arm receiving standard care alone. The trial's primary endpoint was sleep quality examined by the Leeds Sleep Evaluation Questionnaire (LSEQ). The trial's secondary endpoints were symptoms alleviation by Day 7, intensive care unit admission, 10-day mortality, white blood cell count, lymphocyte count, C-reactive protein status, and peripheral capillary oxygen saturation. Ninety-six patients were recruited and allocated to either the melatonin arm (n = 48) or control arm (n = 48). Baseline characteristics were similar across treatment arms. There was no significant difference in symptoms on Day 7. The mean of the LSEQ scores was significantly higher in the melatonin group (p < 0.001). There was no significant difference in laboratory data, except for blood oxygen saturation, which has improved significantly in the melatonin group compared with the control group (95.81% vs. 93.65% respectively, p = 0.003). This clinical trial study showed that the combination of oral melatonin tablets and standard treatment could substantially improve sleep quality and blood oxygen saturation in hospitalized COVID-19 patients., (© 2021 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
22. Evaluation of Antiphospholipid Antibodies in COVID-19 Patients with Coagulopathy.
- Author
-
Nosrati A, Torabizadeh Z, Kheirkhah D, Vahedi Larijani L, Alizade-Navaei R, Mobini M, Aliyali M, Abedi S, and Mehravaran H
- Abstract
Background: Due to the importance of recent published studies regarding the thrombotic events in COVID-19 patients, the purpose of this study was to evaluate the frequency of antiphospholipid antibodies in COVID-19 patients with coagulopathy., Materials and Methods: The present cross-sectional study was conducted on COVID-19 patients with coagulopathy admitted to Imam Khomeini Hospital in Sari, Iran, between June and September in 2020. Later on, the levels of anti-phospholipid antibodies (aPL-ab) and biochemical factors were measured., Results: This study was performed on 40 patients. Individuals who were positive for at least one of the aPL-ab were classified in the group of aPL-ab positive; according to which 29 patients (72.5%) had no positive aPL-ab and 11 patients (27.5%) had at least one positive aPL-ab. 8 patients were only positive for lupus anticoagulant (LA) assay, one patient had B2GPI- IgM, one patient had aCL-IgG and only one patient had two positive simultaneous tests for LA and aCL-IgG. Thrombotic events have been found in 7 patients (17.5%) of which, three patients with deep vein thrombosis, one patient with pulmonary embolism, two patients with stroke, and one patient with myocardial infarction. The values of aPTT for the screening of Lupus anticoagulant assay were significantly different between the two groups, although there was no significant difference between the two groups in the co-morbidities, disease severity, death and laboratory tests (P> 0.05)., Conclusion: Despite the high incidence of thrombotic complications reported in COVID-19 patients in the current study, the levels of antiphospholipid antibodies had no significant correlation with the occurrence of thromboembolic events and disease outcome in COVID-19 patients with coagulopathy., (Copyright© 2022 National Research Institute of Tuberculosis and Lung Disease.)
- Published
- 2022
23. Alkaline phosphatase and score of HRCT as indicators for predicting the severity of COVID-19.
- Author
-
Sharifpour A, Safanavaei S, Tabaripour R, Taghizadeh F, Nakhaei M, Abadi A, Fakhar M, Banimostafavi ES, Nazar E, Aliyali M, Abedi S, Mehravaran H, Zakariaei Z, and Azadeh H
- Abstract
Background: The clinical symptoms, blood laboratory data, O2 saturation and high-resolution computed tomography (HRCT) findings are critical factors in diagnosis of COVID-19 infection., Methods: In this study, 105 hospitalized patients suspected of having COVID-19 were evaluated. Finally, the laboratory and HRCT and related factors data of 83 confirmed cases by HRCT and RT-PCR were analyzed. To compare the median of quantitative variables in the two groups, the Mann-Whitney U test was used. Also, to determine the factors associated with the positiveness of the HRCT result, a univariate logistic model was fitted. Moreover, receiver operating characteristic (ROC) curves were constructed to test the ability of the final model to predict the positiveness of HRCT result., Results: 61.40% of the patients had a comorbidity disease. 89.20% had fever, 92.00% cough, 91.40% dyspnea. Abnormal CRP was seen in 77.80% of the patients, followed by 66.70% lymphopenia, and 60.30% neutrophilia. Also, ALP (abnormal vs. normal) and score of HRCT assessment variables had a significant effect on the positiveness of HRCT findings. 87.95% had abnormal HRCT with 41% bilateral multi lobar patchy ground glass opacity (GGO). Moreover, there was a statistically significant association between the level of O2 saturation and HRCT results., Conclusion: Our findings showed that male patients with middle age and comorbidity disease were more susceptible to the COVID-19 infection. Additionally, clinical features, blood laboratory findings, O2 saturation and HRCT findings are critical factors in the prognosis of COVID-19 infection., Competing Interests: None., (© 2021 The Authors.)
- Published
- 2021
- Full Text
- View/download PDF
24. Apoptosis and immunophenotyping of peripheral blood lymphocytes in Iranian COVID-19 patients: Clinical and laboratory characteristics.
- Author
-
Taghiloo S, Aliyali M, Abedi S, Mehravaran H, Sharifpour A, Zaboli E, Eslami-Jouybari M, Ghasemian R, Vahedi-Larijani L, Hossein-Nattaj H, Amjadi O, Rezazadeh H, Ajami A, and Asgarian-Omran H
- Subjects
- Adult, Aged, Apoptosis immunology, Biomarkers blood, COVID-19 immunology, Female, Flow Cytometry, Humans, Iran, Lymphocyte Count, Lymphopenia immunology, Male, Middle Aged, B-Lymphocytes cytology, CD4-Positive T-Lymphocytes cytology, CD8-Positive T-Lymphocytes cytology, Immunophenotyping methods, Killer Cells, Natural cytology, SARS-CoV-2 immunology
- Abstract
A novel member of human coronavirus, named severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been recently recognized in China and rapidly spread worldwide. Studies showed the decreasing of peripheral blood lymphocytes in a majority of patients. In this study, we have reported the clinical features, laboratory characteristics, the frequency of peripheral blood lymphocyte subpopulations, and their apoptosis pattern in Iranian coronavirus infectious disease (COVID-19) patients. Demographic and clinical data of 61 hospitalized confirmed cases with COVID-19 at Imam Khomeini Hospital were collected and analyzed. Peripheral blood mononuclear cells were isolated from all samples and the apoptosis pattern was evaluated using Annexin V/propidium iodide method. The frequency of lymphocyte subsets, including T-CD4
+ , T-CD8+ , NK, B cells, and monocytes, was measured in all patients and 31 controls by flow cytometry. Our findings demonstrated that the percentage of lymphocytes, CD4+ , and CD8+ T cells were decreased in COVID-19 patients compared with the control group. Regarding the clinical severity, the number of lymphocytes, CD4+ , CD8+ T cells, and NK cells were also decreased in severe cases when compared with mild cases. Finally, our data have also indicated the increase in apoptosis of mononuclear cells from COVID-19 patients which was more remarkable in severe clinical cases. The frequency of immune cells is a useful indicator for prediction of severity and prognosis of COVID-19 patients. These results could help to explain the immunopathogenesis of SARS-CoV-2 and introducing novel biomarkers, therapeutic strategies, and vaccine candidates., (© 2020 Wiley Periodicals LLC.)- Published
- 2021
- Full Text
- View/download PDF
25. Cytokine profiling in Iranian patients with COVID-19; association with clinical severity.
- Author
-
Taghiloo S, Soltanshahi M, Aliyali M, Abedi S, Mehravaran H, Ajami A, and Asgarian-Omran H
- Subjects
- Aged, Biomarkers blood, C-Reactive Protein analysis, COVID-19 blood, COVID-19 diagnosis, COVID-19 virology, Case-Control Studies, Cytokine Release Syndrome blood, Cytokine Release Syndrome diagnosis, Cytokine Release Syndrome virology, Female, Host-Pathogen Interactions, Humans, Iran, Lymphocytes immunology, Lymphocytes metabolism, Lymphocytes virology, Male, Middle Aged, Neutrophils immunology, Neutrophils metabolism, Neutrophils virology, SARS-CoV-2 pathogenicity, Severity of Illness Index, COVID-19 immunology, Cytokine Release Syndrome immunology, Cytokines blood, SARS-CoV-2 immunology
- Abstract
Background: SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), is recognized for the first time in Wuhan, China. The cytokine storm is a known factor causing major clinical symptoms leading to death in COVID-19 patients., Objective: To investigate and compare the serum levels of different cytokines in COVID-19 patients with different clinical severity., Methods: Concentrations of serum cytokines, including IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α, IFN-γ, and GM-CSF, were measured in 61 COVID-19 patients and 31 normal controls with ELISA. We investigated the correlation between the levels of these cytokines and clinical severity, CRP level, neutrophil and lymphocyte count in patients with COVID-19., Results: Our data indicated that the levels of IL-1β, IL-2, IL-4, IL-6, IL-8, TNF-α, IFN-γ, and GM-CSF, but not IL-10 were significantly increased in COVID-19 patients compared to normal controls. Statistical analysis showed that the level of IL-1β, IL-2, IL-4, IL-6, IL-8, TNF-α, IFN-γ, and GM-CSF were higher in severe COVID-19 than those of mild cases. The concentrations of all mentioned cytokines were negatively associated with the absolute count of lymphocytes, and positively correlated with the CRP level and the absolute count of neutrophils., Conclusion: The current study suggests that high levels of various cytokines correlate with the disease severity and immunopathogenesis of COVID-19.
- Published
- 2021
- Full Text
- View/download PDF
26. A Bibliometric Analysis of Global Research on Lophomonas Spp. in Scopus (1933-2019).
- Author
-
Keighobadi M, Nakhaei M, Sharifpour A, Khasseh AA, Safanavaei S, Tabaripour R, Aliyali M, Abedi S, Mehravaran H, Banimostafavi ES, and Fakhar M
- Subjects
- Humans, Bibliometrics
- Abstract
Background: This study was designed to analyze the global research on Lophomonas spp. using bibliometric techniques., Methods: A bibliometric research was carried out using the Scopus database. The analysis unit was the research articles conducted on Lophomonas spp., Results: A total of 56 articles on Lophomonas spp. were indexed in the Scopus throughout 1933-2019 (87 years) with the following information: (A) The first article was published in 1933; (B) 21 different countries contributed in studies related to Lophomonas spp.; (C) China ranked first with 16 publications about Lophomonas spp.; and (D) "Brugerolle, G" and "Beams, H.W." from France and the US participated in 4 articles respectively, as the highest number of publications in the Lophomonas spp. network., Discussion: After 87 years, Lophomonas still remains unknown for many researchers and physicians around the world. Further studies with high quality and international collaboration are urgently needed to determine different epidemiological aspects and the real burden of the mysterious parasite worldwide., (Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)
- Published
- 2021
- Full Text
- View/download PDF
27. Identification of Sonographic Features for Predicting Benign Versus Malignant Mediastinal or Hilar Lymph Nodes Using Endobronchial Ultrasound.
- Author
-
Abedini A, Razavi F, Mehravaran H, Toutkaboni MP, Kashefizadeh A, Emami H, Kazempour-Dizaji M, Farahani M, and Kiani A
- Abstract
Objectives: In countries with a high prevalence of tuberculosis, such as Iran, the differentiation of malignant from non-malignant tumors is crucial. We attempted to find a reliable model in determining malignant nodes by investigating the sonographic characteristics of lymph nodes (LNs)., Methods: In this prospective study, the morphologic characteristics of LNs, including size, shape, vascular pattern, echogenicity, margin, coagulation necrosis sign, calcification, and central hilar structure, which had been obtained during endobronchial ultrasound-guided transbronchial needle aspiration, were compared with the final pathology results., Results: We examined 253 LNs from 93 patients. Round shape, non-hilar vascular pattern, heterogeneous echogenicity, hyperechogenicity, distinct margin, and the existence of necrosis signs were significantly higher in malignant nodes. On the other hand, the existence of calcification, as well as the presence of central hilar structure, were highly suggestive of benign nodes ( p < 0.050). Multivariate logistic regression revealed that size > 1 cm, heterogeneous echogenicity, hyperechogenicity, the existence of necrosis signs, and the lack of central hilar structure are independent predictive factors for malignancy. The accuracy of each of the aforementioned characteristics are 42.3%, 71.5%, 71.9%, 73.5%, and 65.6%, respectively. Of 74 malignant LNs, 100% had at least one of these independent factors., Conclusions: The morphological features of LNs based on endobronchial ultrasound-guided transbronchial needle aspiration can play a role in predicting malignancy., (The OMJ is Published Bimonthly and Copyrighted 2020 by the OMSB.)
- Published
- 2020
- Full Text
- View/download PDF
28. Association of Human Cytomegalovirus with Hodgkin’s Disease and Non-Hodgkin’s lymphomas
- Author
-
Mehravaran H, Makvandi M, Samarbaf Zade A, Neisi N, Kiani H, Radmehr H, Shahani T, Hoseini SZ, Ranjbari N, and Nahid Samiei R
- Abstract
Background and Objective: The human cytomegalovirus (HCMV) can persist lifelong as a latent infection and may result in a series of disorders. Associations with both Hodgkin’s disease and non-Hodgkin´s lymphomas have been reported. Expression of the unique long (UL)138 gene of HCMV is linked with the viral latency phase while that of the immediate-early (IE)1 gene is typical of the viral replication phase in patients. This study conducted to determine the prevalence of CMV latent infection in histological tissue samples from patients with Hodgkin’s and Non-Hodgkin´s lymphomas. Material and Methods: A cross sectional study was carried out with a total of 50 paraffin embedded tissues blocks, including 25 samples for Hodgkin’s disease and 25 samples for non-Hodgkin´s lymphomas. After RNA extraction and cDNA preparation, detection of IE1 mRNA was conducted by RT-PCR and identification of mRNA UL138 was achieved by nested PCR. Results: Among 25 cases of Non-Hodgkin´s lymphoma, 5 (20%) were positive for UL 138 and 1 (4%) for both IE1 and UL 138. Among 25 cases of Hodgkin only 1 (4%) was positive for UL 138 and all were negative for IE1 .Conclusion: A relatively high 20% rate of expression of UL 138 was detected in patients with non-Hodgkin´s lymphoma, so that latent CMV infection may play a role in development of the disease., (Creative Commons Attribution License)
- Published
- 2017
- Full Text
- View/download PDF
29. Frequency of Epstein Barr Virus Type 1 Among Nasopharyngeal Carcinomas in Iranian Patients
- Author
-
Shahani T, Makvandi M, Samarbafzadeh A, Teimoori A, Ranjbar N, saki N, Nikakhlagh S, Neisi N, Hosseini Z, Pourrezaei S, Shabani A, Radmehr H, Mehravaran H, Kiani H, and Haghi A
- Abstract
Background: Around 95% of the world’s population are infected with the Epstein-Barr virus (EBV), which can persist latent in B lymphocytes and epithelial cells life-long. EBV has been linked with lymphoid and epithelial cancers and persistence of EBV infection in lymphoid or epithelial cells may result in virus-associated B-cell tumors or nasopharyngeal carcinomas (NPC). This study was conducted to determine the frequency of EBV DNA in nasopharyngeal carcinoma tissue of Iranian patients. Materials and methods: A total of 50 blocks of formalin-fixed paraffin-embedded tissue of NPCs from 38 (76 %) male and 12 (24%) female patients were collected from archives of Ahvaz hospitals. Sections were cut at 5 μm and DNA was extracted for detection of EBV DNA and EBV typing by mested PCR. DNA sequencing was performed to confirm PCR results. The distribution of EBV DNA was compared among WHO histological subtypes of NPC. Results: Some 3 female and 11 (22%) male NPC samples showed positive for EBV DNA type 1, 2/14(22.2%)WHO histological type II and 12/41(29.3%) WHO histological type III. Conclusions: The frequency of EBV DNA among NPCs in Iranian patients was found to be 28%, EBV type I predominating. Both WHO histological type II and III NPC subtypes demonstrated approximately the same detection prevalence., (Creative Commons Attribution License)
- Published
- 2017
- Full Text
- View/download PDF
30. Prevalence of Hepatitis C virus Genotype 3a in patients with Hodgkin and Non-Hodgkin Lymphoma.
- Author
-
Radmehr H, Makvandi M, Samarbafzadeh A, Teimoori A, Neisi N, Rasti M, Abasifar S, Soltani H, Abbasi S, Kiani H, Mehravaran H, Azaran A, and Shahani T
- Abstract
Background and Objectives: Hepatitis C virus (HCV) is a major public health problem worldwide. Replication and persistence of HCV genome have been described in the liver tissue as well as B cells lymphocyte. Several investigations have reported that long-term persistence of HCV in B cells may result in Hodgkin and Non-Hodgkin lymphoma. This study was aimed to determine frequency of HCV RNA in histological tissues obtained from patients suffered from Hodgkin and Non-Hodgkin lymphoma., Materials and Methods: 52 formalin-fixed paraffin-embedded tissue blocks including 23 (44.3%) Hodgkin and 29 (55.7%) Non-Hodgkin samples were collected and five micrometer sections were prepared. RNA was extracted and cDNA was synthesized. Two consecutive Nested RT-PCR assays were carried out for detection of HCV 5' UTR and core gene. RT-PCR products were sequenced and aligned to construct HCV phylogenic tree to evaluate the homology of sequences in comparison to the reference sequences retrieved from Genbank., Results: Overall, 6 Non-Hodgkin (20.6%) and 3 Hodgkin lymphoma (13.04%) samples showed positive PCR results for both 5' UTR and HCV core RNA via nested PCR ( P <0.469). Sequencing results revealed that all detected HCV RNA samples belonged to the genotype 3a., Conclusion: Despite low prevalence of HCV infection in Iran, high frequency of HCV RNA genotypes 3a (17.3%) has been found in patients with Hodgkin and Non-Hodgkin lymphoma. To improve treatment regimens, screening of HCV RNA in patients suffered from Hodgkin or Non-Hodgkin lymphoma is recommended which can be done through highly sensitive molecular means before and after immunosuppression status.
- Published
- 2016
31. Association of HHV-6 with Hodgkin and non Hodgkin lymphoma.
- Author
-
Kiani H, Makvandi M, Samarbafzadeh A, Teimoori A, Nisi N, Mehravaran H, Radmehr H, Hosseini Z, Haghi A, Shahani T, Varnaseri M, and Ranjbari N
- Abstract
Background and Objectives: Human Herpes 6 virus (HHV-6) could remain latent and chronic in the host cells after primary infection. HHV-6 genome encodes certain transactivation proteins which may results in development of malignant lymphoma. The association of human herpes six virus (HHV-6) infection and Hodgkin and Non-Hodgkin lymphomas is strongly supported by epidemiological studies. The aim of this study was to determine the prevalence of HHV-6 among the patients with Hodgkin, Non-Hodgkin's lymphoma., Materials and Methods: Overall 44 blocks of formalin-fixed, paraffin-embedded of the patients including 22(50%) Hodgkin and 22(50%) Non-Hodgkin Lymphoma were collected. Initially the section of 5μm-thickness were prepared from the formalin-fixed, paraffin-embedded tissue blocks. Then the deparaphinazation was carried out for each sample. The DNA was extracted, followed by nested PCR for detection of HHV-6. Based on PCR product size and sequencing, the HHV-6 A or B subtypes were characterized., Results: 12/22(54.54%) cases of Hodgkin and 8/22 (36.36%) Non-Hodgkin's lymphoma were shown as positive for HHV-6. Out of 12 positive HHV-6 in Hodgkin lymphoma, 10 patients (45.45%) belonged to variant A while 2 cases (9.09%) were found positive for both HHV-6A and HHV-6B. All the Non Hodgkin samples (n=8, 36.36%) showed positive for HHV-6 variant A., Conclusion: High prevalence of HHV-6 was found among the patients with Hodgkin and Non-Hodgkin's lymphoma. Two patients with Hodgkin lymphoma had mixed HHV-6A and HHV-6B infections. It is recommended patients with Hodgkin and Non-Hodgkin should be screened for HHV-6 detection before chemotherapy.
- Published
- 2016
32. Impact of Comorbid Ischemic Heart Disease on Short-Term Outcomes of Patients Hospitalized for Acute Exacerbations of COPD.
- Author
-
Aliyali M, Mehravaran H, Abedi S, Sharifpour A, and Yazdani Cherati J
- Abstract
Background: Ischemic heart disease (IHD) is a leading cause of mortality and morbidity in patients with COPD. The contribution of IHD to acute outcomes in patients with acute exacerbation of COPD (AECOPD) is not known in detail. The present study assessed the effect of comorbid IHD on length of stay (LOS), risk of intensive care unit (ICU) admission and death as indicators of the short-term outcomes for patients hospitalized for AECOPD., Materials and Methods: Medical records of patients hospitalized for AECOPD from September 2008 to March 2014 were reviewed. Data extracted from patient records regarding the presence of comorbidities and the markers of disease severity were analyzed using logistic regression for ICU admission and mortality, the Kaplan-Meier method, log rank test and Cox regression for LOS., Results: Of 507 separate admissions, 146 episodes (28.8%) occurred in patients with IHD. The median LOS was 7 days [interquartile range (IQR) 6, 11] in patients with IHD versus 6 days (IQR 5, 8) for patients without IHD. After adjustment for confounders, LOS was found to be 26% longer (p=0.033) for patients with IHD. The adjusted odds ratio for the risk of ICU admission and death in patients with IHD was 2.97 and 3.86, respectively., Conclusion: Patients hospitalized for AECOPD with comorbid IHD had longer LOS, greater risk for ICU admission and death. It seems that this group is a particular COPD subtype with a more severe degree of COPD and poorer acute outcomes that may influence optimal management.
- Published
- 2015
33. Changeover in the molecular and atomic fluorine laser transitions.
- Author
-
Mehravaran H, Parvin P, and Dorranian D
- Subjects
- Computer Simulation, Fluorine chemistry, Lasers, Models, Chemical, Spectrum Analysis methods
- Abstract
Measurements of molecular and atomic fluorine laser emissions were done from 2?psi (absolute) to 5?atm to determine pressure-dependent spectral lines. While at low pressures, the atomic transitions are dominant; however, both atomic and molecular transitions are detected simultaneously at atmospheric pressures above approximately 2?atm, where a changeover occurs. The excitation mechanisms are strongly dependent on the excited and ionized He species within the gain medium. Initially it affects the atomic transitions of the submanifolds and the corresponding molecular transition takes place via collisional events. The gain competitions among the doublet and quartet atomic transitions have also been investigated.
- Published
- 2010
- Full Text
- View/download PDF
34. Acoustic effects of metal vapor lasers.
- Author
-
Zoghi M, Parvin P, Behrouzinia S, Salehinia D, Khorasani K, and Mehravaran H
- Abstract
Some fluctuations in the output power of a copper vapor laser with a 16 mm bore were recorded by varying the excitation frequency from 13 to 33 kHz. The effect arises from the laser tube, which performs both as an optical and an acoustic resonator at the acoustic resonant frequencies. It is shown that a similar effect occurs in other metal vapor and copper halide lasers as well.
- Published
- 2009
- Full Text
- View/download PDF
35. Spectral Lines of the Atomic-Fluorine Laser from 2 psi (absolute) to 5.5 atm.
- Author
-
Parvin P, Mehravaran H, and Jaleh B
- Abstract
Various lines of atomic fluorine laser have been studied over a wide pressure range for determination of the relative intensity of each pressure-dependent line. In this investigation, the most probable laser pumping mechanisms have been verified.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.